Abstract
A phase I BNCT trial in glioblastoma started at the
Finnish BNCT facility in May 1999. The aim of the present
work was to verify the doses calculated in treatment
planning and estimate the whole body dose on the basis of
neutron fluence and gamma dose measurements in vivo and
in a whole body phantom. Neutron fluence and gamma dose
measurements were made with 55Mn activation foils and
7LiF:Mg,Cu,P TL detectors, respectively. Detector pairs
or gamma detectors alone were placed on the patients
(entrance surface and accessible upper body cavities) and
in a modified water-filled whole body phantom.
The calculated and measured neutron fluences and absorbed
gamma doses correlated well within the uncertainties in
the phantom measurements as well as in the patient
measurements. Despite the different alignment of the two
treatment fields in the head, the measured body doses
have been approximately the same in all patients, e.g. in
the umbilicus 40 plus/minus 10 mGy.
| Original language | English |
|---|---|
| Title of host publication | Program & Abstracts of 9th International Symposium on Neutron Capture Therapy for Cancer |
| Place of Publication | Osaka |
| Pages | 117-118 |
| Publication status | Published - 2000 |
| MoE publication type | B3 Non-refereed article in conference proceedings |
| Event | 9th International Symposium on Neutron Capture Therapy for Cancer: NCT Osaka 2000 - Osaka, Japan Duration: 2 Oct 2000 → 6 Oct 2000 |
Conference
| Conference | 9th International Symposium on Neutron Capture Therapy for Cancer |
|---|---|
| Country/Territory | Japan |
| City | Osaka |
| Period | 2/10/00 → 6/10/00 |